idec-159
mAbexperimentalADC
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2005 (NCT00102024)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor-associated antigen 72INHIBITOR
Tumor-associated antigen 72 inhibitor
- TAG72Immunity, passive
TAG72 immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- 90-yttrium
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109576 ↗
Also known as
- idec-159
- idec-159
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00102024 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2005 | Biogen, University of Alabama, Birmingham |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biogen | For profit | 1 | 1 | 1 | 2005 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 0 | 1 | 2005 |
2 organizations
Page 1 / 1